Migraines, the multiple sclerosis prodrome, and multiple sclerosis susceptibility
Abstract
BACKGROUND: Multiple studies identified an association between migraines and multiple sclerosis (MS).
OBJECTIVE: To investigate whether migraines increase MS risk or are part of the MS prodrome.
METHODS: Incident MS cases and matched controls completed structured interviews that included a detailed headache and MS history. Participants were classified as having migraines if they fulfilled the third edition of the International Classification of Headache Disorders criteria. The association between migraine onset concurrent with or before the first MS symptom/index date was estimated using multivariable logistic regression.
RESULTS: Among the 591 MS cases (70.6% females, 42.0% White), 21.2% developed migraines concurrent with or before the onset of MS compared to 18.7% of the 651 controls (70.4% females, 42.1% White, adjusted odds ratio (aOR) = 1.15, 95% confidence interval (CI) = 0.87-1.53). Migraine onset was more likely to occur either concurrently or 1 year before MS symptom onset/index date among MS cases (n = 18, 14.4%) than controls (n = 8, 6.6%; aOR = 2.52, 95% CI = 1.08-5.86, p = 0.032). However, not when restricted to only those with migraine onset before MS onset.
CONCLUSION: Migraine was associated with an increased odds of MS only when co-occurrence was considered. These findings imply that migraines are part of the constellation of MS onset symptoms rather than a risk factor for or prodromal symptom of MS.
How strong is the evidence?
Evidence Hub reads this as a case-control, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 18 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.